News

Biomedical Systems, a premier global provider of centralized diagnostic services, announced its affiliation with the Electronic Patient-Reported Outcome (ePRO) Consortium, a program run by the Critical Path Institute (C-Path).

ACI Clinical announces a new solution for Life Sciences companies facing the growing difficulty surrounding the identification and engagement of independent medical experts.

Series of research projects to evaluate approaches for improving patient understanding of clinical trials

Christa Wirthumer-Hoche, PhD, head of the Austrian Medicines and Medical Devices Agency, has been elected Vice-Chair of the European Medicines Agency (EMA) by the Management Board for a three-year period.

Palatin Technologies is a biotech company focused on developing targeted, receptor-specific, peptide therapeutics for the treatment of diseases with significant, unmet medical needs and commercial potential.

New faces among the Pharma Industry rise the ranks.

Whether we are referring to CSRs or to IPD, the personal information of trial participants needs to be de-identified prior to release. This article will describe the available methods for de-identifying clinical trial data, and the relative strengths and weaknesses of each.

SureClinical Inc., an industry-leader in collaborative cloud health sciences applications, announced today a strategic partnership with Triumph Consultancy Services to broaden its eTMF service delivery portfolio.

To celebrate 20 years since its opening, the European Medicines Agency (EMA) organized a one-day meeting this week. Called “Science, Medicines, Health: Patients at the heart of future innovation”, the invitation-only event in London focused on the EMA’s future role

Clinical trial site engagement has been advocated as a critical component relating to a study’s performance and success, however, a minimum amount of data supports this connection.

Annual ASCO Report Shows Widespread Disturbance in Oncology Practice, Amid Growing Patient Demand and Administrative Burden

A new study by the American Society of Clinical Oncology (ASCO) is now available, which chronicles the current realities of the cancer care system and examines trends in the oncology workforce.

BRANY has successfully continued its Full Accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).

 Sentiment analysis can give health care organizations a competitive edge in understanding what customers think about their healthcare experience, to help reduce costs and improve care service and to lead to new clinical research and treatments. In addition, it taps into a new channel of pharmacovigilance input information that can enable Marketing Authorization Holders to keep abreast of opinions on the safety of their products in real time.

WIRB-Copernicus Group (WCG), the world’s largest provider of regulatory and ethical review services and software to support clinical research, announced today that its Western Institutional Review Board® company has been certified to ISO 9001:2008 by BSI.

Over the years, clinical study management has become more fragmented. There are more organizations participating in a study, each bringing their own experiences, interpretations of requirements including how quality is defined. How is it possible that requirements and quality be interpreted so differently?

BBK Worldwide, a clinical trial marketing firm announced it is making the availability of its mobile apps My Clinical Study Buddy®for patients and My Protocol Pal® for investigators free of charge throughout 2015.

Patient focused drug development (PFDD) is moving into the mainstream, promising to alter the conduct of clinical trials and FDA regulatory policies.

An important criterion for a well-conducted clinical trial is minimization of bias in endpoint assessment.

Biomedical Systems, a premier global provider of centralized diagnostic services, launches its second generation clinical outcome assessment software offering three easy-to-use platforms to collect patient data.

?Lund, Sweden-based Dignitana, a manufacturer of medical cooling devices, engaged CRO Target Health in 2011 toward its approval of DigniCap® System, its product to protect cells and hair for patients in chemotherapy treatment.